Previous 10 | Next 10 |
Nevro (NVRO +5.8%) director Kevin C Oboyle bought 2400 shares of the company, as per the SEC statement. At the price range of $83.75-$83.80, Oboyle spent around $201K on shares. The moves takes his direct beneficial ownership to 13,318 shares. Quick look at the company's ownership compos...
Nevro Announces Three Podium Presentations from SENZA-PDN and SENZA-NSRBP Clinical Trials Have Been Accepted for Late-Breaking Abstract Sessions at NANS 2022 Annual Meeting SENZA-PDN 18-Month Follow-Up Results, 12-Month Crossover Results and Analysis of Healthcare Resource Utili...
Nevro to Present at 40th Annual J.P. Morgan Healthcare Conference Monday, January 10, 2022 at 7:30 am Pacific Time / 10:30 am Eastern Time PR Newswire REDWOOD CITY, Calif. , Dec. 10, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device ...
Nevro Announces Two Health Economic Poster Presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2021 Meeting Six-Month Healthcare Resource Utilization Data from SENZA-PDN Randomized Controlled Trial Resulted in Reduction of the La...
Nevro Announces Three Important Clinical Data Publications for Treating Painful Diabetic Neuropathy with 10 kHz Therapy Twelve-Month Data From Landmark SENZA-PDN Randomized Controlled Trial Show HFX for PDN Significantly and Durably Reduces Painful Diabetic Neuropathy Symptoms a...
Shares of Nevro Corp. (NVRO +3.6%) are up in trading today after a member of the board of director purchased ~$1.7M worth of shares. An SEC filing indicates that Elizabeth Weatherman bought 20K shares yesterday ranging from $84.29 to $85.27 per share. She now owns 38,328 shares, including 3,1...
The following slide deck was published by Nevro Corp. in conjunction with their 2021 Q3 earnings call. For further details see: Nevro Corp. 2021 Q3 - Results - Earnings Call Presentation
Truist has downgraded shares of Nevro (NVRO -8.0%) to hold from buy citing uncertainty of the timing and magnitude of the spinal cord stimulation market in the U.S. The firm has also cut its price target to $105 from $165 (~4% decline). Analyst David Rescott writes that while painful diabetic...
Nevro Corp. (NVRO) Q3 2021 Earnings Conference Call November 08, 2021 04:30 PM ET Company Participants Julie Dewey - Vice President-Investor Relations and Corporate Communications Keith Grossman - Chairman, Chief Executive Officer and President Rod MacLeod - Chief Financial Officer Conference...
Nevro (NYSE:NVRO): Q3 GAAP EPS of -$1.44 misses by $0.57. Revenue of $93.21M (-14.1% Y/Y) beats by $1.62M. Press Release For further details see: Nevro EPS misses by $0.57, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024 PR Newswire REDWOOD CITY, Calif. , July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-chan...
Nevro to Present at Truist Securities MedTech Conference PR Newswire REDWOOD CITY, Calif. , June 11 , 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chr...
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 PR Newswire REDWOOD CITY, Calif. , May 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the trea...